by Fred Dumais | Aug 2, 2022 | News Release
Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million1 Canadians suffering from dry eye disease and 400,0002 Canadians suffering from open-angle glaucoma or ocular hypertension Valeo to start recognizing...
by Fred Dumais | Jun 14, 2022 | News Release
Q2-22 revenues of $4.8 million, up 80% over Q2-21Q2-22 gross margins of $1.7 million, up 134% over Q2-21Canadian provincial public reimbursement now complete for Enerzair® Breezhaler® and Atectura® Breezhaler® with the addition of British Columbia and...
by Fred Dumais | Jun 8, 2022 | News Release
MONTREAL, QUEBEC , June 8, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2022 on...
by Fred Dumais | Apr 28, 2022 | News Release
MONTREAL, QUEBEC , April 28, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announces the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
by Fred Dumais | Apr 25, 2022 | News Release
MONTREAL, QUEBEC , April 25, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a...
by Fred Dumais | Apr 19, 2022 | News Release
MONTREAL, QUEBEC, April 19, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the “Debentures”)...
